Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK Champions More Trial Data Disclosure, But PhRMA Objects

Executive Summary

In its latest move on the transparency front, Glaxo endorses the U.K.-driven AllTrials campaign, which calls for releasing all clinical trial results. Announcement runs counter to PhRMA’s defense against requirements for more disclosure.

You may also be interested in...



European Notebook: EMA Conflict Of Interest Rules; EU Unitary Patent; EMA Adverse Event Literature Screening

EMA tightens rules on the revolving door between industry and scientific (if not regulators); the European unitary patent proposal survives Spain's judicial challenge; Switzerland amends its drug pricing procedures, and more in this month's column.

JAMA Studies Provide More Ammunition For Trial Disclosure Reformers

JAMA studies focus on the high number of terminated and unreported trials, plus discrepancies in publicly reported trial results. Publication comes as the Institute of Medicine consults stakeholders about trial data sharing and ahead of new reporting laws in Europe.

U.K. Public Spending Panel Urges More Clinical Data Access, Sharing

Influential U.K. parliamentary panel keeps the pressure up on making clinical trial data more widely available, including greater sharing between regulators and health technology assessors.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1125120

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel